-
11.
Stimvia Completes Pilot Study and Announces Promising Initial Results for Potential Parkinson's Disease Add-On Treatmen
-
(News)
-
... Parkinson's Disease, Stimvia plans substantial investment in further clinical trials to validate the method's efficacy and safety. We believe our technology can introduce new, additive treatment modalities ...
-
12.
Baptist Health, Caregility Expand Partnership to Enhance Patient Care
-
(Press Releases)
-
... The initiative adds virtual clinical resources to support in-person bedside care and help improve patient outcomes. This collaboration underscores both organizations’ commitment to leveraging technology ...
-
13.
A New Therapeutic Target for Traumatic Brain Injury
-
(News)
-
... This fibrin-targeting immunotherapy protects from multiple sclerosis and Alzheimer's disease in mice. A humanized version of this first-in-class fibrin immunotherapy is already in Phase 1 safety clinical ...
-
14.
Thermo Fisher Scientific Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing
-
(News)
-
... designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion.
As a result, cell therapy manufacturers can use CTS ...
-
15.
Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System
-
(Press Releases)
-
... PICO sNPWT provides better clinical outcomes than standard dressings in patients at high risk of surgical site infections (SSIs), at similar overall cost. As a result, NICE has reconfirmed its guidance, ...
-
16.
CLEAR GUIDE SCENERGY™ Device for Transperineal Interventions
-
(Press Releases)
-
... While we always believed it would have a profound impact on cancer screenings, the clinical results for transperineal interventions have been truly remarkable," says Clear Guide Medical CMO Dr. Nick Karahalios. ...
-
17.
GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies
-
(News)
-
... side effects can be severe.2 In addition to the potential benefits of these AI models in clinical use, with roughly 5,000 immunotherapies in development today3, selecting patients more likely to respond ...
-
18.
First Postpartum Depression Pill, Research Led by Northwell Health’s Feinstein Institutes
-
(News)
-
... depression (PPD) – a condition one in eight birthing women experience.
The decision is the culmination of decades of preclinical research done by scientists worldwide and the most recent clinical trials, ...
-
19.
Metrodora Institute, a Leader in Treating Complex Conditions, Chooses the Ivenix Infusion System
-
(Press Releases)
-
... medical and research center dedicated to treating neuroimmune axis disorders.
“The Ivenix system’s adaptability makes it incredibly easy to use in clinical trials and in providing necessary infusion ...
-
20.
Tumoroid Culture Medium to Accelerate Development of Novel Cancer Therapies
-
(Press Releases)
-
... therapies to patients, with up to 97% of drug candidates failing in clinical trialsii. More closely resembling donor tissue than traditional 2D cell models, patient-derived tumoroids – cultures of tumor ...
